Skip to main content
Erschienen in:

30.09.2023 | Sarcoma

Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial

verfasst von: Sylvie Bonvalot, MD, PhD, Nathalie Cozic, PhD, Axel Le Cesne, MD, Jean Yves Blay, MD, PhD, Nicolas Penel, MD, PhD, Magali Fau, MD, Christine Chevreau, MD, Philippe Anract, MD, Denis Waast, MD, Valérie Laurence, MD, Sarah Watson, MD, PhD, Florence Duffaud, MD, François Gouin, MD, Sophie Taieb, MD, Michèle Kind, MD, Laurent Lam, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Stabilization or spontaneous regressions are demonstrated in more than half of patients affected by primary desmoid-type fibromatosis (DF) in retrospective studies. The objective of this phase II study was to prospectively assess the behavior of primary sporadic DT managed by active surveillance (AS).

Methods

This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall. At inclusion, all patients were initially placed on AS. Follow-up was based on clinical and radiological evaluation by magnetic resonance imaging (MRI) performed at 1, 3, 6, 9, and 12 months, and then every 6 months for 3 years. The primary endpoint was progression-free survival (PFS) at 3 years according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as evaluated by a Central Review Board.

Results

Between 2012 and 2015, 100 patients were enrolled. The female/male ratio was 8 and the median age was 34 years (interquartile range [IQR] 30.8–43.9). Median follow-up was 46.6 months (IQR 36.8–61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5–63.1%). At progression (48 patients), 23 patients received active treatment. Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs). The median time to PR was 31.7 months (25.3–not available).

Conclusions

These data support the use of AS as the primary approach to select patients with peripheral DF who require aggressive treatment.
Literatur
2.
Zurück zum Zitat Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34:462–8.CrossRefPubMed Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34:462–8.CrossRefPubMed
3.
Zurück zum Zitat Fiore M, Rimareix F, Mariani L, et al. Desmoid- type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.CrossRefPubMed Fiore M, Rimareix F, Mariani L, et al. Desmoid- type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.CrossRefPubMed
4.
Zurück zum Zitat Bonvalot S, Ternes N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20:4096–102.CrossRefPubMed Bonvalot S, Ternes N, Fiore M, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20:4096–102.CrossRefPubMed
5.
Zurück zum Zitat Colombo C, Miceli R, Le Péchoux C, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015;51:186–92.CrossRefPubMed Colombo C, Miceli R, Le Péchoux C, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015;51:186–92.CrossRefPubMed
6.
Zurück zum Zitat Penel N, Le Cesne A, Bonvalot S, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125–31.CrossRefPubMed Penel N, Le Cesne A, Bonvalot S, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125–31.CrossRefPubMed
7.
Zurück zum Zitat Timbergen MJM, Schut AW, Grünhagen DJ, et al. Active surveillance in desmoid-type fibromatosis: A systematic literature review. Eur J Cancer. 2020;137:18–29.CrossRefPubMed Timbergen MJM, Schut AW, Grünhagen DJ, et al. Active surveillance in desmoid-type fibromatosis: A systematic literature review. Eur J Cancer. 2020;137:18–29.CrossRefPubMed
8.
Zurück zum Zitat Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107.CrossRef Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107.CrossRef
9.
Zurück zum Zitat Colombo C, Fiore M, Grignani G, et al. A prospective observational study of active surveillance in primary desmoid fibromatosis. Clin Cancer Res. 2022;28(18):4027–32.CrossRefPubMed Colombo C, Fiore M, Grignani G, et al. A prospective observational study of active surveillance in primary desmoid fibromatosis. Clin Cancer Res. 2022;28(18):4027–32.CrossRefPubMed
13.
Zurück zum Zitat Fiore M, Bonvalot S, Personeni G, et al. Impact of pregnancy in women with desmoid fibromatosis: An international retrospective observational study. J Clin Oncol. 2023;41(Suppl 16):11513.CrossRef Fiore M, Bonvalot S, Personeni G, et al. Impact of pregnancy in women with desmoid fibromatosis: An international retrospective observational study. J Clin Oncol. 2023;41(Suppl 16):11513.CrossRef
14.
Zurück zum Zitat Mikhael R, Smith M, Tzanis D, Watson S, Miah AB, Bonvalot S. Desmoid tumors: who, when and how to treat? Curr Opin Oncol. 2022;34(4):335–41.CrossRefPubMed Mikhael R, Smith M, Tzanis D, Watson S, Miah AB, Bonvalot S. Desmoid tumors: who, when and how to treat? Curr Opin Oncol. 2022;34(4):335–41.CrossRefPubMed
15.
Zurück zum Zitat Improta L, Tzanis D, Bouhadiba T, Abdelhafidh K, Bonvalot S. Desmoid tumours in the surveillance era: What are the remaining indications for surgery? Eur J Surg Oncol. 2020;46(7):1310–4.CrossRefPubMed Improta L, Tzanis D, Bouhadiba T, Abdelhafidh K, Bonvalot S. Desmoid tumours in the surveillance era: What are the remaining indications for surgery? Eur J Surg Oncol. 2020;46(7):1310–4.CrossRefPubMed
16.
Zurück zum Zitat Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29(26):3553–8.CrossRefPubMed Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol. 2011;29(26):3553–8.CrossRefPubMed
17.
Zurück zum Zitat Penel N, Bonvalot S, Bimbai A, et al. Pain in patients with desmoid fibromatosis (DF). Ann Oncol. 2022;33(Suppl 7):S681–700. Penel N, Bonvalot S, Bimbai A, et al. Pain in patients with desmoid fibromatosis (DF). Ann Oncol. 2022;33(Suppl 7):S681–700.
18.
Zurück zum Zitat Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119(20):3696–702.CrossRefPubMed Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119(20):3696–702.CrossRefPubMed
19.
Zurück zum Zitat Penel N, Bonvalot S, Bimbai AM, et al. Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis. Clin Cancer Res. 2022;28(18):4105–11.CrossRefPubMed Penel N, Bonvalot S, Bimbai AM, et al. Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis. Clin Cancer Res. 2022;28(18):4105–11.CrossRefPubMed
Metadaten
Titel
Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial
verfasst von
Sylvie Bonvalot, MD, PhD
Nathalie Cozic, PhD
Axel Le Cesne, MD
Jean Yves Blay, MD, PhD
Nicolas Penel, MD, PhD
Magali Fau, MD
Christine Chevreau, MD
Philippe Anract, MD
Denis Waast, MD
Valérie Laurence, MD
Sarah Watson, MD, PhD
Florence Duffaud, MD
François Gouin, MD
Sophie Taieb, MD
Michèle Kind, MD
Laurent Lam, PhD
Publikationsdatum
30.09.2023
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 13/2023
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14341-2

Neu im Fachgebiet Chirurgie

Leitlinienkonformes Management thermischer Verletzungen

Thermische Verletzungen gehören zu den schwerwiegendsten Traumen und hinterlassen oft langfristige körperliche und psychische Spuren. Die aktuelle S2k-Leitlinie „Behandlung thermischer Verletzungen im Kindesalter (Verbrennung, Verbrühung)“ bietet eine strukturierte Übersicht über das empfohlene Vorgehen.

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Nackenschmerzen nach Bandscheibenvorfall: Muskeltraining hilft!

Bei hartnäckigen Schmerzen aufgrund einer zervikalen Radikulopathie schlägt ein Team der Universität Istanbul vor, lokale Steroidinjektionen mit einem speziellen Trainingsprogramm zur Stabilisierung der Nackenmuskulatur zu kombinieren.

US-Team empfiehlt Gastropexie nach Hiatushernien-Op.

Zur Vermeidung von Rezidiven nach Reparatur einer paraösophagealen Hiatushernie sollte einem US-Team zufolge der Magen bei der Op. routinemäßig an der Bauchwand fixiert werden. Das Ergebnis einer randomisierten Studie scheint dafür zu sprechen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.